<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="25013">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01822314</url>
  </required_header>
  <id_info>
    <org_study_id>FM-12-B01</org_study_id>
    <secondary_id>2012-003481-41</secondary_id>
    <nct_id>NCT01822314</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Chemotherapy With Nab-paclitaxel in Women With HER2-negative High-risk Breast Cancer</brief_title>
  <acronym>ETNA</acronym>
  <official_title>Neoadjuvant Chemotherapy With Nab-paclitaxel in Women With HER2-negative High-risk Breast Cancer &quot; ETNA (Evaluating Treatment With Neoadjuvant Abraxane)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione Michelangelo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GEICAM</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Breast Cancer Research Centre WA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Centre, Singapore</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fondazione Michelangelo</source>
  <oversight_info>
    <authority>Italy: The Italian Medicines Agency</authority>
    <authority>Italy: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Solvent-based taxanes (paclitaxel, docetaxel) cause severe toxicities not only by the active
      agents itself but also by the solvents like cremophor. Nab-paclitaxel (Abraxane®) is a
      solvent-free formulation of paclitaxel encapsulated in albumin. It does not require
      premedication with corticosteroids or antihistamines to prevent the risk of solvent-mediated
      hypersensitivity reactions. This new formulation improves safety profile, allows higher
      dosing with shorter infusion duration, and produces higher tumor drug concentration.

      As neoadjuvant treatment does not only allow to compare competing treatment approaches with
      a very high quality (homogenous treatment population, precise assessment of response by
      histological assessment), but also to identify predictive markers, this trial will compare
      weekly nab-paclitaxel followed by AC or EC or FEC before surgery with solvent-based
      paclitaxel followed by Adriamycin,Cyclophosphamide (AC) or Epirubicin,Cyclophosphamide  (EC)
      or Fluorouracil,Epirubicin,Cyclophosphamide (FEC) before surgery.

      In the study several Immunohistochemistry (IHC) and molecular assays will be performed
      before and during the period of chemotherapy administration and at surgery with the goal of
      defining a marker of efficacy to be later validated in a larger adjuvant setting.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">October 2025</completion_date>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>pathologic Complete Response (pCR)</measure>
    <time_frame>At the time of surgery: 40 months after the randomization of the first patient</time_frame>
    <safety_issue>No</safety_issue>
    <description>To compare the rate of pathologic Complete Response  (pCR, absence of invasive disease in breast and nodes (ypT0/ypTis, ypN0)) for abraxane (Abraxane®, abraxane) vs paclitaxel.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>clinical Overall Response (cOR)</measure>
    <time_frame>At the time of surgery: 40 months after the randomization of the first patient</time_frame>
    <safety_issue>No</safety_issue>
    <description>To compare the rate of clinical overall response (cOR) after the first 4 cycles of abraxane vs paclitaxel and to compare the rate of cOR after the entire preoperative chemotherapy (i.e. before surgery) in the study arms of abraxane vs paclitaxel</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event Free Survival (EFS)</measure>
    <time_frame>5 years after the first patient in and 10 years after randomization of last patient in</time_frame>
    <safety_issue>No</safety_issue>
    <description>To compare the  Event Free Survival (EFS, i.e. disease progression while on primary therapy or disease recurrence after surgery) in the study arms of abraxane vs paclitaxel</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant Event Free Survival (DEFS)</measure>
    <time_frame>5 years after the first patient in and 10 years after randomization of last patient in</time_frame>
    <safety_issue>No</safety_issue>
    <description>The distant event free survival (DEFS) is defined as the time from randomization to the first date of distant metastasis while on primary therapy or distant recurrence after surgery or death due to any cause. Patients who terminate the study without evidence of any of the above events will be censored at the date of their last follow-up tumor assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local Event Free Survival</measure>
    <time_frame>5 years after the first patient in and 10 years after randomization of last patient in</time_frame>
    <safety_issue>No</safety_issue>
    <description>The local event free survival (LEFS) is defined as the time from randomization to the first date of local progression while on primary therapy or local recurrence after surgery. Rules for censoring and methods of analysis will be the same as defined for EFS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Regional Event Free Survival</measure>
    <time_frame>5 years after the first patient in and 10 years after randomization of last patient in</time_frame>
    <safety_issue>No</safety_issue>
    <description>The regional event free survival (REFS) is defined as the time from randomization to the first date of regional progression while on primary therapy or regional recurrence after surgery. Rules for censoring and methods of analysis will be the same as defined for EFS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>13 years from the date of first patient in</time_frame>
    <safety_issue>No</safety_issue>
    <description>The overall survival (OS) is defined as the time from randomization to the date of death. Patients alive at the end of study will be censored at their last contact date.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability</measure>
    <time_frame>Each participant will be followed for the duration of treatment period, approximately 9 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Patients will be assessed for adverse events by clinical examination, questioning for symptoms of toxicity, laboratory assessments, vital signs, ECG and LVEF.
Neurological toxicity and other toxicities will be assessed throughout the study according the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Event (CTCAE) Version 4.0.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">632</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Paclitaxel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Paclitaxel at the dosage of 90 mg/m2 diluted in 250 mL of water for injection (WFI) over 1 hour given week 1, 2 and 3 followed by 1 week rest to be repeated for 4 cycles followed by AC  or EC (adriamycin or epirubicin and cyclophosphamide) on day 1 every 3 weeks for 4 cycles or FEC (fluorouracil, epirubicin, and cyclophosphamide) on day 1 every three weeks for 4 cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Abraxane</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Abraxane at the dosage of 125 mg/m2 over 30 minutes given week 1, 2 and 3 followed by 1 week rest to be repeated for 4 cycles followed by AC  or EC (adriamycin or epirubicin and cyclophosphamide) on day 1 every 3 weeks for 4 cycles or FEC (fluorouracil, epirubicin, and cyclophosphamide) on day 1 every 3 weeks for 4 cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abraxane</intervention_name>
    <arm_group_label>Abraxane</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <arm_group_label>Paclitaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adriamycin or epirubicin and Cyclophosphamide (AC or EC) or Fluorouracil, epirubicin and Cyclophosphamide (FEC)</intervention_name>
    <description>AC  or EC (adriamycin or epirubicin and cyclophosphamide) on day 1 every 3 weeks for 4 cycles or FEC (fluorouracil, epirubicin, and cyclophosphamide) on day 1 every 3 weeks for 4 cycles</description>
    <arm_group_label>Paclitaxel</arm_group_label>
    <arm_group_label>Abraxane</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female patients aged 18 years or older

          -  Histologically confirmed invasive unilateral breast cancer

          -  HER2-negative disease (defined as 0-1+ by immunohistochemistry or 2+ by
             immunohistochemistry without HER2 amplification by either FISH, CISH, or other
             amplification tests done locally)

          -  Known hormone receptor status (estrogen receptor [ER], progesterone receptor [PgR]),
             tumor grade and, if institutional standard permits, known Ki67 value

          -  Available paraffin-embedded tumor block taken at diagnostic biopsy for central
             confirmation of HER2 eligibility, hormone receptor status, Ki67 value and biomarker
             evaluation is mandatory

          -  One of the following clinical stages:

          -  T2, T3, T4 disease, triple negative (HER2, ER, PgR)

          -  T2, T3, T4 disease, ER or PgR positive and moderately differentiated or poorly
             differentiated  tumor grade (G II-III)

          -  ECOG performance status 0 or 1

          -  Written informed consent to participate in the trial (approved by the Institutional
             Review Board [IRB]/ Independent Ethics Committee [IEC]) obtained prior to any study
             specific screening procedures

          -  Willing and able to comply with the protocol

        Exclusion Criteria:

          -  Synchronous contralateral breast cancer or presence of metastatic disease (M1).
             Exception: contralateral insitu ductal cancer

          -  Surgical axillary staging procedure prior to study entry. Exceptions: 1) Fine needle
             aspiration (FNA) of an axillary node is permitted for any patient, and 2) although
             not recommended, a pre-neoadjuvant therapy sentinel lymph node biopsy for patients
             with clinically negative axillary nodes is permitted

          -  Pregnant or lactating women. Documentation of a negative pregnancy test must be
             available for premenopausal women with intact reproductive organs and for women less
             than one year after the last menstrual cycle

          -  Women with childbearing potential unless (1) surgically sterile or (2) using adequate
             measures of contraception, for example  abstinence, an intra-uterine device, or
             double barrier method of contraception

          -  Treatment including radiation therapy, chemotherapy, biotherapy, and/or hormonal
             therapy for the currently diagnosed breast cancer prior to study entry

          -  Previous investigational treatment for any condition within 4 weeks of randomization
             date

          -  Patients on therapy with a strong CYP3A4 inhibitor and on therapy with Warfarin
             (Coumadin)

          -  Previous or concomitant malignancy of any other type that could affect compliance
             with the protocol or interpretation of results. Patients with curatively treated
             basal cell carcinoma of the skin or in situ cervix cancer are generally eligible.

          -  Pre-existing motor or sensory neuropathy of grade &gt; 1 for any reason

          -  Patients with a history of hypersensitivity due to drugs containing polyoxyethylene
             castor oil (Cremophor EL) (e.g., ciclosporin), or hardened castor oil (e.g., vitamin
             preparations for injection, etc.)

          -  Other serious illness or medical condition including: history of documented
             congestive cardiac failure; angina pectoris requiring anti-anginal medication;
             evidence of transmural infarction on ECG; poorly controlled hypertension (e.g.
             systolic &gt;180 mm Hg or diastolic &gt;100 mm Hg; however, patients with hypertension
             which is well controlled on medication are eligible); clinically significant valvular
             heart disease; high-risk uncontrolled arrhythmias

          -  Patients with a history of uncontrolled seizures, central nervous system disorders or
             psychiatric disability judged by the investigator to be clinically significant and
             precluding informed consent or adversely affecting compliance with study drugs

          -  Serious uncontrolled infections (bacterial or viral) or poorly controlled diabetes
             mellitus

          -  Any of the following abnormal baseline hematological values:

               1. Absolute Neutrophil Count (ANC) &lt; 1.5 x 10^9/L

               2. Platelet count &lt; 100 x 10^9/L

               3. Hemoglobin (Hb) &lt; 10 g/dL

          -  Any of the following abnormal baseline laboratory tests

               1. Serum total bilirubin &gt; 1.5 x ULN (upper limit of normal) (except for patients
                  with clearly documented Gilbert's syndrome)

               2. Alanine transaminase (ALT) or aspartate transaminase (AST)&gt; 1.25 x ULN

               3. Alkaline phosphatase &gt; 2.5 x ULN

               4. Serum creatinine &gt; 1.5 x ULN

          -  Baseline left ventricular ejection fraction (LVEF) &lt; 50% by echocardiography or
             multi-gated scintigraphic scan (MUGA)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luca Gianni, MD</last_name>
    <role>Study Chair</role>
    <affiliation>San Raffaele Hospital, Milan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pinuccia Valagussa</last_name>
    <phone>+39 022390</phone>
    <phone_ext>3071</phone_ext>
    <email>pinuccia.valagussa@fondazionemichelangelo.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elisa Coradeschi, Biol</last_name>
    <phone>+39 022390</phone>
    <phone_ext>3451</phone_ext>
    <email>elisa.coradeschi@fondazionemichelangelo.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>500</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Sid Selva-Nayagam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peter McCallum Cancer Centre</name>
      <address>
        <city>East Melbourne</city>
        <state>Victoria</state>
        <zip>8006</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>David Speakman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Eastern Health Breast Cancer Research Maroondah Breast Clinic</name>
      <address>
        <city>Ringwood East</city>
        <state>Victoria</state>
        <zip>3135</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jacqui Chirgwin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Hospital - Breast Clinical Trials Unit</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Arlene Chan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Perth Hospital</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Andrew Redfern, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Niels-Stensen Kliniken Franzinkus-Hospital Harderberg</name>
      <address>
        <city>Hardenberg</city>
        <state>Harderberg</state>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Albert von der Assen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Aachen Frauenklinik für Gynäkologie und Geburtsmedizin</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Dirk Bauerschlag, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Augsburg International Patient Service</name>
      <address>
        <city>Augsburg</city>
        <zip>86156</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Arthur Wischnik, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Frauenarzt-Zentrum-Zehlendorf</name>
      <address>
        <city>Berlin</city>
        <zip>14169</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Gerd Graffunder, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Augusta-Kranken-Anstalt gGmbH Klinik für Hämatologie, Onkologie &amp; Palliativmedizin</name>
      <address>
        <city>Bochum</city>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dirk Behringer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Erlangen - Frauenklinik - Poliklinik</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Michael Patrick Lux, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bethanien-Krankenhaus Onkologisches Zentrum</name>
      <address>
        <city>Frankfurt</city>
        <zip>60389</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Hans Tesch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Agaplesion Markus Hospital - Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <zip>60389</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Marc Thill, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mammazentrum - Hamburg am Krankenhaus Jerusalem</name>
      <address>
        <city>Hamburg</city>
        <zip>20357</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Pia Wülfing, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gynäkologisch-Onkologische Praxis</name>
      <address>
        <city>Hannover</city>
        <zip>30177</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Hans Joachim Lück, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St.Elisabeth-Krankenhaus Brustzentrum</name>
      <address>
        <city>Köln</city>
        <zip>50935</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Giese Helling, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Interdisciplinary Oncology Center</name>
      <address>
        <city>Munich</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Wolfang Eiermann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Praxis Gynäkologie Arabella</name>
      <address>
        <city>Munich</city>
        <zip>81925</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Anita Prechtl, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Onkologische Schwerpunktpraxis</name>
      <address>
        <city>Speyer</city>
        <zip>67346</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Judith Franz-Werner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cliniche Gavazzeni - Humanitas Gavazzeni</name>
      <address>
        <city>Bergamo</city>
        <state>BG</state>
        <zip>24125</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Pier Mario Salvini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico Sant'Orsola Malpighi</name>
      <address>
        <city>Bologna</city>
        <state>BO</state>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Claudio Zamagni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IST San Martino</name>
      <address>
        <city>Genova</city>
        <state>GE</state>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Lucia Del Mastro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. San Gerardo</name>
      <address>
        <city>Monza</city>
        <state>MB</state>
        <zip>20050</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Paolo Bidoli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. Ospedale Civile di Legnano</name>
      <address>
        <city>Legnano</city>
        <state>MI</state>
        <zip>20025</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sergio Fava, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. Ospedale Luigi Sacco</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20160</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Elena Piazza, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Istituto nazionale dei tumori</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Angela Moliterni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. Ospedale Niguarda Ca' Granda</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Salvatore Siena, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Luca Gianni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ULSS 15 Alta Padovana</name>
      <address>
        <city>Camposampiero</city>
        <state>PD</state>
        <zip>35012</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Fernando Gaion, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <state>PV</state>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Paolo Pedrazzoli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione Salvatore Maugeri</name>
      <address>
        <city>Pavia</city>
        <state>PV</state>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Lorenzo Pavesi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arcispedale Santa Maria Nuova</name>
      <address>
        <city>Reggio Emilia</city>
        <state>RE</state>
        <zip>42123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Corrado Boni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Università Istituto di Clinica Medica</name>
      <address>
        <city>Sassari</city>
        <state>SS</state>
        <zip>07100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Maria Giuseppina Sarobbo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute for Cancer Research and treatment</name>
      <address>
        <city>Candiolo</city>
        <state>TO</state>
        <zip>10060</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Filippo Montemurro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Santa Maria della Misericordia</name>
      <address>
        <city>Udine</city>
        <state>UD</state>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mauro Mansutti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. Ospedale di Circolo</name>
      <address>
        <city>Busto Arsizio</city>
        <state>VA</state>
        <zip>21052</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Marco Bregni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Presidio Ospedaliero di Saronno</name>
      <address>
        <city>Saronno</city>
        <state>VA</state>
        <zip>21047</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Claudio Verusio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ULSS n. 13 - Presidi ospedalieri di Mirano</name>
      <address>
        <city>Mirano</city>
        <state>VE</state>
        <zip>30035</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mario Bari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda ULSS 6 di Vicenza</name>
      <address>
        <city>Vicenza</city>
        <state>VI</state>
        <zip>36100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Laura Merlini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Miguel Servet University Hospital</name>
      <address>
        <city>Zaragoza</city>
        <state>Aragon</state>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Antonio Anton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Lozano Blesa</name>
      <address>
        <city>Zaragoza</city>
        <state>Aragon</state>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Raquel Andrés, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Son Llàtzer Palma de Mallorca</name>
      <address>
        <city>Palma de Mallorca</city>
        <state>Baleares</state>
        <zip>2002</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Isabel Garau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Corporacio Sanitaria Parc Tauli</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Miguel Angel Segui Palmer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Consorci Sanitari de Terrassa</name>
      <address>
        <city>Terrassa</city>
        <state>Barcelona</state>
        <zip>08227</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Angels Arcusa Lanza, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundacion Alcorcón</name>
      <address>
        <city>Alcorcón</city>
        <state>Madrid</state>
        <zip>28922</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Carlos Jara Sánchez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Canarias</name>
      <address>
        <city>La Laguna</city>
        <state>Tenerife</state>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Norberto Batista, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Oncologico de Galicia</name>
      <address>
        <city>A Coruña</city>
        <zip>15009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Manuel Ramos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Alicante</name>
      <address>
        <city>Alicante</city>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Josè Ponce, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol</name>
      <address>
        <city>Badalona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Beatriz Cirauqui, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ignasl Tusquets, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic i Provencial</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Montserrat Munoz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital San Pedro de Alcantara</name>
      <address>
        <city>Caceres</city>
        <zip>10003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Santiago Gonzalez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofía</name>
      <address>
        <city>Córdoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Juan de la Haba-Rodriguez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Onkologikoa</name>
      <address>
        <city>Donostia</city>
        <zip>20014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Arrate Plazaola, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Jaen</name>
      <address>
        <city>Jaen</city>
        <zip>23007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Pedro Sanchez Rovira, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Teresa Herrera (Chuac)</name>
      <address>
        <city>La Coruna</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Lourdes Calvo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Arnau de Vilanove de Lleida</name>
      <address>
        <city>Lleida</city>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Serafin Morales Murillo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gregorio Maraňón Hospital</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Miguel Martin Jiménez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center Madrid</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Antonio Gonzalez Martin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Beatriz Castelo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>J.M. Morales Meseguer, Universitary Hospital Marques in los Velez</name>
      <address>
        <city>Murcia</city>
        <zip>30080</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Elena Garcia Martinez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Cesar A. Rodriguez, Md</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Donostia</name>
      <address>
        <city>San Sebastián</city>
        <zip>20080</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Isabel Alvarez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41071</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Luis de la Cruz Merino, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Manuel Ruiz Borrego, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Salud</name>
      <address>
        <city>Toledo</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>José L. Chacón, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto Valenciano Oncologia</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Angel Guerrero, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universita Valencia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Begoña Bermejo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Nuestra Señora de Sonsoles</name>
      <address>
        <city>Ávila</city>
        <zip>05004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>José E. Alés-Martinez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 20, 2014</lastchanged_date>
  <firstreceived_date>March 25, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>breast</keyword>
  <keyword>cancer</keyword>
  <keyword>unilateral</keyword>
  <keyword>non metastatic</keyword>
  <keyword>HER2 negative</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
